Improving the Odds in Advanced Breast Cancer With Combination Immunotherapy: Stepwise Addition of Vaccine, Immune Checkpoint Inhibitor, Chemotherapy, and HDAC Inhibitor in Advanced Stage Breast Cancer.
BN-Brachyury
TGF-β
bintrafusp alfa
entinostat
metastatic breast cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
07
2020
accepted:
23
12
2020
entrez:
22
3
2021
pubmed:
23
3
2021
medline:
23
3
2021
Statut:
epublish
Résumé
Breast tumors commonly harbor low mutational burden, low PD-L1 expression, defective antigen processing/presentation, and an immunosuppressive tumor microenvironment (TME). In a malignancy mostly refractory to checkpoint blockade, there is an unmet clinical need for novel combination approaches that increase tumor immune infiltration and tumor control. Preclinical data have guided the development of this clinical trial combining 1) BN-Brachyury (a poxvirus vaccine platform encoding the tumor associated antigen brachyury), 2) bintrafusp alfa (a bifunctional protein composed of the extracellular domain of the TGF-βRII receptor (TGFβ "trap") fused to a human IgG1 anti-PD-L1), 3), entinostat (a class I histone deacetylase inhibitor), and 4) T-DM1 (ado-trastuzumab emtansine, a standard of care antibody-drug conjugate targeting HER2). We hypothesize that this tetratherapy will induce a robust immune response against HER2
Identifiants
pubmed: 33747894
doi: 10.3389/fonc.2020.581801
pmc: PMC7977003
doi:
Types de publication
Journal Article
Langues
eng
Pagination
581801Informations de copyright
Copyright © 2021 Gatti-Mays, Gameiro, Ozawa, Knudson, Hicks, Palena, Cordes, Steinberg, Francis, Karzai, Lipkowitz, Donahue, Jochems, Schlom and Gulley.
Déclaration de conflit d'intérêts
CP is an inventor in NIH patents related to brachyury. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2018 Nov 29;379(22):2108-2121
pubmed: 30345906
Proc Natl Acad Sci U S A. 2019 Feb 26;116(9):3678-3687
pubmed: 30733298
Cancer Immunol Res. 2018 Dec;6(12):1561-1577
pubmed: 30341213
JAMA Oncol. 2019 Aug 01;5(8):1205-1214
pubmed: 30973611
Oncoimmunology. 2018 Feb 14;7(5):e1426519
pubmed: 29721396
Oncogene. 2012 Jul 5;31(27):3223-34
pubmed: 22056872
Adv Cancer Res. 2015;128:69-93
pubmed: 26216630
Cancer Immunol Res. 2015 Dec;3(12):1375-85
pubmed: 26297712
Oncoimmunology. 2017 Jul 13;6(10):e1349589
pubmed: 29123964
Hum Pathol. 2018 Feb;72:28-34
pubmed: 28843709
Breast Cancer Res. 2012 Sep 11;14(5):R123
pubmed: 22967435
Oncoscience. 2018 Aug 22;5(11-12):269-270
pubmed: 30652109
Clin Cancer Res. 2012 Jul 15;18(14):3868-79
pubmed: 22611028
J Immunother Cancer. 2018 Sep 18;6(1):91
pubmed: 30227893
Nat Rev Clin Oncol. 2020 Feb;17(2):91-107
pubmed: 31570827
J Clin Oncol. 2016 Oct 10;34(29):3511-3517
pubmed: 27298406
NPJ Breast Cancer. 2019 Oct 8;5:34
pubmed: 31602395
Clin Cancer Res. 2018 Jun 15;24(12):2804-2811
pubmed: 29559561
Control Clin Trials. 1989 Mar;10(1):1-10
pubmed: 2702835
Cancer Res. 2005 Jun 15;65(12):5153-62
pubmed: 15958559
Breast Cancer Res Treat. 2011 Jul;128(2):347-56
pubmed: 20730488
J Clin Oncol. 2016 Jul 20;34(21):2460-7
pubmed: 27138582
Endocr Relat Cancer. 2016 Oct;23(10):783-796
pubmed: 27580659
Sci Transl Med. 2015 Nov 25;7(315):315ra188
pubmed: 26606967
Oncologist. 2020 Jul;25(7):560-e1006
pubmed: 31876334
J Circ Biomark. 2016 Mar 10;5:5
pubmed: 28936253
Clin Cancer Res. 2018 Mar 15;24(6):1287-1295
pubmed: 29298798
J Immunother Cancer. 2017 Feb 21;5:20
pubmed: 28239472
Oncotarget. 2016 Feb 16;7(7):7390-402
pubmed: 26862729
NPJ Breast Cancer. 2019 Oct 29;5:37
pubmed: 31700993
J Clin Oncol. 2012 Mar 1;30(7):729-34
pubmed: 22291085
Cancer Res. 2014 Apr 1;74(7):1945-57
pubmed: 24520078
J Natl Cancer Inst. 2014 May 09;106(5):
pubmed: 24815864
Breast Cancer Res Treat. 2018 Feb;167(3):671-686
pubmed: 29063313
Cancer Immunol Res. 2015 Nov;3(11):1248-56
pubmed: 26130065
Oncotarget. 2017 Sep 8;8(43):75217-75231
pubmed: 29088859
Cell. 2015 Aug 27;162(5):961-73
pubmed: 26317465
Clin Cancer Res. 2020 Feb 1;26(3):704-716
pubmed: 31645354
Oncoimmunology. 2018 Jul 30;7(11):e1466018
pubmed: 30377559
J Immunother Cancer. 2020 Mar;8(1):
pubmed: 32188703
Oncoimmunology. 2018 Jul 30;7(10):e1490854
pubmed: 30386679
Expert Opin Biol Ther. 2020 Jul;20(7):705-709
pubmed: 32159390
N Engl J Med. 2016 Sep 1;375(9):819-29
pubmed: 27433843
Science. 2017 Jul 28;357(6349):409-413
pubmed: 28596308
J Immunother Cancer. 2020 Feb;8(1):
pubmed: 32079617
Arch Pathol Lab Med. 2020 May;144(5):545-563
pubmed: 31928354
Clin Cancer Res. 2017 Nov 15;23(22):6833-6845
pubmed: 28855356